Evidence map›Paper›PMID 39359733›Full record

ArticleFrontiers in immunology2024

SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2.

Chao Niu, Tingting Liang, Yongchong Chen, Shan Zhu, Lei Zhou, Naifei Chen, Lei Qian, Yufeng Wang, Min Li, Xin Zhou and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chao NiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Tingting LiangCancer Center, The First Hospital of Jilin University, Changchun, China.
Yongchong ChenCancer Center, The First Hospital of Jilin University, Changchun, China.
Shan ZhuCancer Center, The First Hospital of Jilin University, Changchun, China.
Lei ZhouCancer Center, The First Hospital of Jilin University, Changchun, China.
Naifei ChenCancer Center, The First Hospital of Jilin University, Changchun, China.
Lei QianCancer Center, The First Hospital of Jilin University, Changchun, China.
Yufeng WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Min LiCancer Center, The First Hospital of Jilin University, Changchun, China.
Xin ZhouCancer Center, The First Hospital of Jilin University, Changchun, China.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cytokine release syndrome (CRS) is one of the leading causes of mortality in patients with COVID-19 caused by the SARS-CoV-2 coronavirus. However, the mechanism of CRS induced by SARS-CoV-2 is vague. Methods: Using spike protein combined with IL-2, IFN-γ, and TNF-α to stimulate human peripheral blood mononuclear cells (PBMCs) to secrete CRS-related cytokines, the content of cytokines in the supernatant was detected, and the effects of NK, T, and monocytes were analyzed. Results: This study shows that dendritic cells loaded with spike protein of SARS-CoV-2 stimulate T cells to release much more interleukin-2 (IL-2,) which subsequently cooperates with spike protein to facilitate PBMCs to release IL-1β, IL-6, and IL-8. These effects are achieved via IL-2 stimulation of NK cells to release tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), as well as T cells to release IFN-γ Mechanistically, IFN-γ and TNF-α enhance the transcription of CD40, and the interaction of CD40 and its ligand stabilizes the membrane expression of toll-like receptor 4 (TLR4) that serves as a receptor of spike protein on the surface of monocytes. As a result, there is a constant interaction between spike protein and TLR4, leading to continuous activation of nuclear factor-κ-gene binding (NF-κB). Furthermore, TNF-α also activates NF-κB signaling in monocytes, which further cooperates with IFN-γ and spike protein to modulate NF-κB-dependent transcription of CRS-related inflammatory cytokines. Discussion: Targeting TNF-α/IFN-γ in combination with TLR4 may represent a promising therapeutic approach for alleviating CRS in individuals with COVID-19.

Indexed as

COVID-19Cytokine Release SyndromeInterleukin-2SARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesCytokinesDendritic CellsHumansInterferon-gammaKiller Cells, NaturalLeukocytes, MononuclearNF-kappa BToll-Like Receptor 4Tumor Necrosis Factor-alphaCytokinesInterferon-gammaInterleukin-2NF-kappa BSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Toll-Like Receptor 4Tumor Necrosis Factor-alphaCD40cytokine release syndromemonocyteNF-κBSARS-CoV-2spike protein

Identifiers

PMID39359733
PMCPMC11445618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.